VELRAYDY Trademark
VELRAYDY is a USPTO trademark filed by Genzyme Corporation. Status: Pending.
Prosecution Summary
Trademark Summary
The mark VELRAYDY is a standard character word mark covering pharmaceutical preparations for treating and preventing somatostatin-expressing neuroendocrine tumors, oncological, gastrointestinal, and hepatological diseases and disorders, including rare forms, cancer, and radiopharmaceuticals primarily in International Class 005, along with classes 006, 018, 044, 046, 051, and 052. It is owned by Genzyme Corporation, a Delaware corporation based in Cambridge, Massachusetts. Notice of Allowance issued on March 10, 2026; applicant must file a Statement of Use or extension request within six months.
Recent Activity
Filed on July 25, 2025, under intent-to-use basis, the application advanced quickly with approval for publication on December 11, 2025, and
Trademark Facts
| Mark | VELRAYDY |
|---|---|
| Serial Number | 99303003 |
| Status | Pending |
| Filing Date | 2025-07-25 |
| Mark Type | Word |
| Nice Classes | 005 (Pharmaceuticals) |
| Owner | Genzyme Corporation |
| Attorney of Record | Alexandra Kochian |
| Prosecution Events | 12 |
| Latest Event | NOAM on 2026-03-10 |
Goods & Services
Pharmaceutical preparations for the treatment and prevention of somatostatin-expressing neuroendocrine tumors; Pharmaceutical preparations for the treatment and prevention of oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical preparations for the treatment and prevention of rare oncological, gastrointestinal, and hepatological diseases and disorders; Pharmaceutical products for the prevention and treatment of cancer; Radiopharmaceutical preparations for the treatment of oncological, gastrointestinal, and hepatological diseases and disorders